NovoCure Ltd - 8-K Filing

NovoCure's Optune Pax receives approval in Japan for the treatment of unresectable locally advanced pancreatic cancer. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits(d) ExhibitsExhibit No)

SEC EDGAR ·

Tickers: $NVCR

Read the full article at SEC EDGAR

More Regulatory news